Last reviewed · How we verify

NCT04771624

Assessment of Executive Functions After Covid-19

Completed Last updated 9 November 2021
What this trial tests

trial in Covid19 in 128 participants. Completed in 1 November 2021.

Timeline
30 October 2020
Primary endpoint
30 April 2021
1 November 2021

Quick facts

Lead sponsorSaglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment128
Start date30 October 2020
Primary completion30 April 2021
Estimated completion1 November 2021
Sites1 location across Turkey (Türkiye)

Conditions studied

Sponsor

Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital

Who can join

18 and older, any sex, with Covid19 or Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

As it is evident that Covid-19 may have some impacts on cognition, the primary aim of this study is to investigate -if any- deficits of attention, working memory and executive functions after Covid-19.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

Other Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04771624.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing